We investigate a body of data emanating from the 2008/9 EU Pharmaceutical Sector Inquiry, interpreting the collection of submissions to it as a concerted attempt at market innovation that becomes fraught with challenge and contest. In the pharmaceutical market, interests associated with patient concerns, government budgets, global "Big Pharma", and local "small pharma" coalesce and compete with patent law, technological innovation and drug lifecycles. Our research question is: What role do market narratives play in shaping the market's sociotechnical agencements? By introducing market narratives, we focus on the performative effects of temporality and iteration. Our argument is that by acting as (contested) promissories, market narratives contribute to "agencing" a market, such that actors are engaged continually in juxtaposing and adjusting their representations of it and putting in place those sociotechnical agencements that make the markets resemble those narratives. Narrating a market becomes a collective and iterative task of equipping actors to shape the markets that they desire.
Introduction
Previous research in market studies has demonstrated that markets are not stable back-cloths of market actors' activities, but that markets and market activities stand in a reciprocal relationship: Markets allow, encourage, or hinder market actors' activities at the same time as these activities shape the markets in which they take place (e.g. Slater 2002; Callon and Muniesa 2005; Kjellberg and Helgesson 2006; Çalişkan and Callon 2010) . Market studies research has also pointed to a reciprocal relationship between market representations and market activities (Kjellberg and Helgesson 2006) , but has arguably failed to explore this link in greater detail. In this paper, we investigate the role of the regulator, via the mechanism of a European Sector Inquiry, in shaping or, more specifically, innovating a market, defined here as "disrupting how actors carry out their market activities." We ask the question: What role do market representations, such as the competing narratives emerging from these Inquiries, play in innovating and shaping a market's sociotechnical agencements?
We seek answers to this question by tracing how, through the means of public narratives, market actors attempt to defend, draw attention to, distract from, condemn, or implicate others in certain market practices. The purpose of such narratives, of course, is to represent market practices and the market to which they relate in a manner most advantageous to the narrating actor. But, as Kjellberg and Helgesson (2006) have highlighted, representing market practices is first and foremost a means of shaping these practices, and this emerges clearly in narratives.
A critical feature of narratives is that they are "promissory" in that they mobilize future states, invoking these descriptions in current disputes to support some practices and discredit others. Narratives also depict past happenings as events, interpreting these as being either favorable or unfavorable to how a market is shaped at present. We assert that narratives, supporting narratives, and counter-narratives about market practices act twofold: One, by claiming stakes in a market with a view to justifying and solidifying existing practices or proposing new ones; two, by bringing into being the market as narrated through creating what Butler (2010, 147) calls "socially binding consequences". In turn, these consequences shape the market's sociotechnical agencements, which we define, with Cochoy (2014) , as textual and material assemblage with the power of agency. In keeping with this idea, we define market narratives as emplotted market representations that participate in mobilizing a market's future sociotechnical agencements. Moving conceptual discussions in market studies beyond market representations, our paper sees market narratives as promissories that invoke and enable future markets and thus as powerful tools in innovating markets, or indeed, in defending markets and their practices against others' innovative plans.
As our opening vignette indicates, the market in question is the pharmaceutical market. At the risk of simplifying what are highly complex issues, this market is caught between two broad discourses in the economics of innovation (eg, Nelson and Winter, 1982) : The first discourse revolves around enhancing welfare through firms' research and development (R&D) activities and novel medicines being made available through market entry, imitation and price competition, so becoming affordable. The second discourse is one of firms' R&D activities being subject to the incentives of expected monopolistic rents, supported by patents that protect intellectual property from imitation for a period of time. Davis and Abraham (2013) explain that pharmaceutical regulation is aimed primarily at reconciling these two discourses by balancing the pharmaceutical producers' commercial and monopolistic interests with the welfare and health interests of consumers and society. Simply put, the regulator has to ask "if I give a pharmaceutical firm monopolistic protection through a drug patent now, how certain is it that the firm will reinvest these monopolistic rents into more socially beneficial R&D activities? And how can competition be encouraged to help make this drug affordable and accessible in the long run?" In doing so, regulation has to anticipate the future effects of current socio-technical agencements.
Davis and Abraham see pharmaceutical innovation as the quintessential "promissory science", "mak [ing] promissory claims about the social/health value of the new technology/drug, which create powerful expectations about (and hence demands for) that technology within wider society, including patients" (ibid., p. 14). Finch and Geiger (2011) investigate the material bases of market innovations in the pharmaceutical industry, demonstrating the pressures in this particular industry to continually destabilize its own markets. Thus, fundamentally, the industry's economic, technological, and societal raisons d'être point toward the future; a future beset by uncertainties, but nonetheless a future that market actors have to anticipate and agree on in the present in order to make it happen.
As promissories, the two discourses on pharmaceutical innovation come to the fore in the narratives that market actors deploy. They emerge over the questions of, for instance, "how much regulation," "how much patent protection,"
and "what is "good" innovation." As we examine in this paper, the ways in which actors work out answers to these questions shape the socio-technical agencements put in place in the pharmaceutical market.
Our study is based on the document trail from the European Commission's recent attempts to introduce innovation among the market practices of originator pharmaceutical companies -those companies which are R&D intensive -in relation to the "lifecycle management" of their drugs. The EU Commission did so by way of a Sector Inquiry into suspected anti-competitive practices in the pharmaceutical industry. The aim of the Sector Inquiry was to ascertain whether there existed any evidence of systematic practices of delaying market entry of generic pharmaceuticals through agreements between competitors. The European Commission suspected that if such agreements existed, they would deter innovation in the pharmaceutical industry and cause substantial costs to tax payers by extending the breadth and duration of the patent protection awarded to producers.
In the remainder of this paper, we will investigate, through the examples of the controversy emanating from this Inquiry's texts, what role market narratives play in agencing markets. Our conceptual approach draws from theories of performativity and markets as sociotechnical agencements, as developed by Callon and others, as well as from the sociology of expectations (Brown and Michael 2003) . We use this conceptual background to analyze the body of documents available regarding the Sector Inquiry in order to assess how narratives shape a market and its practices. We analyze narratives that support and that contradict the EU's suspicion that producers had developed practices in the pharmaceutical market to exploit patent law by utilizing a "patent management toolkit." We compare and contrast the narratives of the Preliminary Report (November 2008) and those emerging from the submissions to the subsequent Consultation Period of two months with the narrative emerging from the Final Report six months later. The former two are broadly representative of the rival discourses on welfare in the industry, of welfare derived by means of entry and price competition in market, and of welfare derived from producers investing in research and development, reflecting the incentives for securing rents under patent. We conclude the paper by considering the role of market narratives as promissories.
Narratives and their worlds
Narratives play a central role in our understanding of how humans apprehend and attempt to shape the socio-material world. Scholars working in fields as diverse as sociology, anthropology, management, literary studies, and economic history have highlighted the role of discourse, narration, and story-telling in creating what we know as "the economic" (e.g. Beckert 2013; Khaire and Wadhwani 2010; Maurer 2006; Czarniawska 1998; McCloskey 1998) . This body of research indicates that in economic and organizational life, narratives are ubiquitous. Narratives and texts are also translocational: they have the capacity to travel, be it in written or oral form. Moreover, narratives and texts are networks of their own, referring to others through what literary theorists call intertextuality (e.g. Keenoy and Oswick 2004) .
While often used interchangeably, there is a certain hierarchical relationship among texts, narratives, and discourses. For the present purpose, we take texts to be carefully constructed material representations that can, either individually or with reference to other texts, build narratives and represent relatively coherent choices of who, where, when, what, why, and how. These choices often have consequences far beyond the texts themselves. Cooren (2004) , for instance, examines what mundane texts in organizations "do," and concludes that "texts are not foundational; however, they participate, like other agents, in the daily production of organizational life" (p. 374). Narratives provide a temporal sequence and unfold in a plot; they are connected to modes of knowing and communicating and to positioning actors and actions in social life generally (Czarniawska 2004) . Texts and narratives in turn contribute to discourses, or ways of understanding and explaining the world, including "ruling in" and "ruling out" certain ways of talking about a topic or object and of conducting oneself in relation to the topic or object (Grant and Hardy 2003) .
Discourse is often associated with institutionalization (Philips, Lawrence and Hardy 2004) and coalition building (Jones and McBeth 2010) . Narratives, discourses, texts, and their inter-textual connections thus participate in the shaping of social practices, institutions and activities (Potter 1996; Czarniawska 2004 ).
Narratives and Performativity
Pursuing narratives further, we can assess their performative role in enacting markets. Callon (1998) draws upon performativity in arguing that scientific theories and models are implicated in making and shaping markets out of "possible worlds" (Callon 2010) . Callon (2002) reflects that performativity first referred to language, or more precisely to Austin's (1962) treatise on "How to Do Things with Words", before entering the vocabulary of Actor-Network Theory.
This reminds us that market discourses or narratives are rarely constative, or descriptive of a reality 'out there'. Instead, they work in and on the market realities that they describe: "The discourse of economics contributes to establishing the reality that it analyses and explains" (Callon 2010, p. 168) .
Drawing on the Austinian tradition of performativity, Butler (2010) emphasizes the role of perlocutionary performativity in economic life, where discourses draw their power from being spread and repeated -what she refers to as iteration and citation. However, this necessity for repetition also introduces space for reflexivity and change (Butler 1999) . For Butler, "performativity never fully achieves its effect, and so in this sense 'fails' all the time; its failure is what necessitates its reiterative temporality, and we cannot think iterability without failure" (2010. p. 153, original emphasis). Thus, and of direct relevance to this paper, statements gain power through iteration, but iteration also makes them 'brokering failure' , which in turn creates space for political debate. As Callon (2010) highlights, Butler's observation points to the plurality of theoretical frameworks accounting for aspects of market functioning and to the fact that any performation produces overflows, or, in Austin's words, "misfires". These misfires
give rise to what Callon (2007 Callon ( , 2010 calls "performation struggles," where the constitution of markets is "constantly tested, criticised, debated, reconstructed and consequently subjected to endless redefinitions and reconfigurations" (Callon 2010, p. 165) when narrated. Thus both Callon and Butler question strongly whether there can ever be a definitive "master narrative".
Following research into performativity, we can expect market representations and narratives to be deployed as part of the normal contests over shaping economic practices, and we find some evidence of this in the research of the fields of market studies and organization studies. Broadly, extant research addressing this issue falls into two categories: studies proximate to the sociology of expectations stream, examining how actors use stories to create a market; and those that examine how market representations are used to justify past market behaviors or actions. The temporality that is so crucial in market narratives' performative power emerges predominantly in the first category of studies, where markets' future effects are debated.
Beckert, (2013) for instance, has highlighted how stories told in the present about the future are creative in paving the way for this future to become possible. For Beckert, (2013, p. 222) economic actors often cope with uncertainty through fictionality, or "present imaginaries of future situations that provide orientation in decision-making despite the uncertainty inherent in the situation."
Fictions can be made to become self-fulfilling prophecies, but this requires considerable concerted investments in the specified futures. Miller and O'Leary (2007) Likewise, Simakova and Neyland (2008) observe the creation and narration of "tellable stories" -"a story which narrates boundaries, relations, agency and identities for entities" (ibid., p. 96) -about a new product in order to develop both a material and imagined world into which that product can be launched. The stories refer to some point of ending, of settling, or of actors being able to halt and also step away from the narrative as an envisaged setting in the future. But this end point is another instance of contest. Pollock and Williams (2010, p. 528) observe a "competition between expectations" in organizing the promissory among industry analysts, where the most successful account is the one that succeeds in helping to convincingly narrate and then create that "new world" (p.
542).
Market representations can help enact futures, but when directed towards solidifying practices they can also be used to contest change, innovation, or disruption. Future-and past-directed narratives thus often work in tandem.
Working from an institutional perspective, Suddaby and Greenwood (2005) observed the discursive struggle between proponents and opponents of a new To summarize, extant literature across the sociology of expectations, market studies, and institutional theory has regarded stories, rhetorics, representations, and fictions as playing an important role in shaping markets.
Extending these arguments, and combining them with Butler's focus on iteration and citation in performativity, we anticipate that narratives as deployed in markets take part in "performation struggles" (Callon 2007 ) in two ways: First, through organizing the passage from one state of affairs to another, they build temporality and causality into the realities they describe, which Czarniawska (2004) calls "emplotment." Second, by weaving a material network of intertextuality, narratives allow for coalition building and claiming stakes, mediating between individual and collective market action, between the economic and the political, and ultimately between futures enacted and futures unfulfilled. It is this aspect of market narratives that we describe in more detail next.
Power, performation struggles and market narratives
Market representations come into being when actors parse, make and offer sense of, or otherwise frame the 'soup' of economic practices -Callon (2009, p. 20 ) has referred to this as "explicitation." However, as we have been arguing above, market representations are much more than sensemaking devices. In order to become "successful" (that is, representational), a statement requires investments in the market's materialities: "To make a formula or auction system work, one has to have tools, equipment, metrological systems, procedures, and so on." (Callon 2007, p. 333) . In turn, the formula or auction system rests on a certain way of thinking about the economic and, crucially, of mobilizing its effects, for instance in the context of "fair and efficient markets" (Muniesa 2003) . By extension, struggles over how to narrate a market do not only happen discursively; the possible worlds that the different narratives evoke will be subjected to "trials of strength" that are often material in nature. As part of a socio-technical agencement, a narrative can literally and materially succeed or fail. Thus, narratives go far beyond a representational idiom. Narrating a market goes hand in hand with efforts to equip that market to correspond to the narrated world.
If narrative practices are involved in performation struggles, they necessarily position their authors in relation to power and authority. Brown (2004) notes, with reference to Michel Foucault's body of work, that master, or what he calls authoritative, narratives can be used to silence alternatives. However, authoritative narratives are not likely to emerge ready-made. More likely there will be a certain amount of public jostling and recruitment among rival narratives.
Discursively, the emphasis in the struggle is enrolment among texts, seen as a particular pattern of intertextuality. A contemporary example of narratives jostling for authority can be seen in the network of tweets and retweets that often emerges around public controversies (e.g. Poell and Bora 2012) . This is not to deny epistemic challenges, which can undermine the authority of a particular text or cluster of texts, but we expect these too to be mediated intertextually.
More broadly, the struggle is between entire sociotechnical agencements, where narrating a market means qualifying its objects and actors' behaviours, thus enabling collective (future) action -or what Pollock and Williams (2010, p. 543) call "world-building activity." Maguire's (2004) study of the substitution of DDT shows such a co-construction of discourse and object through discursive struggles and actor enrolment over time in four related areas: artifact-making, fact-making, opinion-making and rule-making. In relation to the latter, it is worth noting that the role of the law and of national or international regulators in crafting authoritative narratives about and enrolling actors to perform in these markets is a particularly interesting though neglected subject of market studies (Christophers 2013) .
In summary, the point of departure of our current study is in exploring the struggles involved in producing an authoritative narrative of a market and that struggle's consequences on the market's sociotechnical agencements. To do so, we trace the assemblage of an authoritative narrative from its initial drafts through the various supporting or counter-narratives produced for it to its mature form and finally to its performative effects. As illustrated in Figure 1 , we focus on temporality and recruitment in relation to the narratives presented. We assess how these narratives describe and contest past and present market practices, and project and thereby enroll actors into future market practices. The future becomes a vital reference point, referring to ideas of how that future can be a settled one with knowable characteristics, allowing others to tie those descriptions of futures to present understandings of past activities.
(INSERT FIGURE 1 ABOUT HERE)
Examining market narratives
The analyzed body of talk and texts emanates from the EU Pharmaceutical Industry Sector Inquiry, which was launched by the Directorate General . These 96 texts, ranging in size from a few pages to over 500, formed the main body of analyzed documents for this study.
We also analyzed a range of newspaper clips, internet texts, ancillary policy documents, and others as secondary data sources.
(INSERT FIGURE 2 ABOUT HERE) (INSERT TABLE 1 ABOUT HERE) Fairclough (1995) argues that discourse should be analysed at three levels: the textual, the discursive (what people do with texts), and the social (how they represent and are used in cultural and institutional contexts). While being mindful of the first and second levels, our analysis below focuses on the third level, that of social practices, with a particular view to the texts' material consequences. We leaned heavily on Potter (1996) 's exploration of how texts appear to produce facts and how these factual descriptions produce action, and (Potter 1996, 172) , and we first plotted and then compared these choices across submissions. Leaning on Potter's (1996) insights into fact-making in texts, we paid particular attention to the invoking of market actors, the attributions made of market practices to particular actors, stake management, and what Potter calls category entitlement, or how a text builds the credibility of its producer. Rather than assessing the veracity of the statements made in the various texts, we looked for evidence of how the texts were constructed to become "successful", both in fact-making and in using this factmaking to change or stabilize the pharmaceutical market's sociotechnical agencements.
Related to this point, we took account of Potter's distinction between texts' epistemological orientation (those elements in a text that work to establish things as factual) and their action orientation (elements that are oriented to some action or range of actions, with an appreciation that action can produce further facts).
We also noted what Potter calls "offensive" and "defensive" orientations of discourses, where the former is concerned with undermining alternative descriptions and the latter with resisting such discounting. Finally, we traced intertextuality. As formal responses, all submissions referred directly to the Preliminary Report by the EU's Directorate General for Competition, but they also spun a much wider "textscape" (Keenoy and Oswick 2004) across regulatory, legal, and scientific realms. This intertextuality, in particular, allowed us to draw connections between the narratives that individual texts emplotted, to use Czarniawska's (2004) phrase, the broader realm of discourse emerging from the web of texts examined, and the market's agencements.
Analysis
Sector The EU Sector Inquiry into anti-competitive practices in the pharmaceutical industry was not the first of its kind; it followed previous Inquiries in the energy, financial services, and telecommunications industries. The aim of the Pharmaceutical Sector Inquiry was to ascertain whether any evidence of a systematic practice of delaying market entry of generic pharmaceuticals through agreements between competitors could be found. The European Commission suspected that if such agreements existed, they would not only act as a deterrent for innovation in the pharmaceutical industry, but they could also cause substantial additional costs to tax payers by prolonging the period of protection awarded to pharmaceutical companies through patents for medical innovation. The report suggested that originator companies used "a variety of methods"
with the objective of delaying or blocking market entry of generic companies in order to ensure continued revenue streams for their medicines. The main practices of "life cycle management strategies" (PR) identified included:
• Launching multiple patent applications for the same medicine, with filing for up to 1,300 patents EU-wide in relation to a single medicine (so-called • Influencing the distribution and supply chain channels.
In many instances, the Preliminary Report finds that originator companies engage in several or even all of these practices simultaneously. On average, these practices saw generics enter the market about seven months after the expiry of a compound's main patent, though with considerable variations across Member States and across medicines. If generic entry had taken place without these delays, savings across the EU, according to the Preliminary Report, could have been an estimated € 3 billion over the seven year period studied, reducing expenditure for these medicines by more than 5%. While acknowledging the difficulties and bottlenecks that the EU patent regime and national regulator and payer practices present to pharmaceutical companies, the narrative of the inquiry strongly suggests that the originator companies' market practices under investigation "contribute to this" (PR p. 6).
Taken in the round, the narrative of the Preliminary Report is one of a group of market actors -originator companies -using a host of practices allowing each of them to evade competition for their lucrative branded drugs. They are also cast as a group of companies that are purportedly more concerned with protecting ongoing revenue streams than with pharmaceutical innovation or any other notion of public good. In the Preliminary Report, this is a master narrative, which fundamentally is a claim of anticompetitive behavior, its adverse consequences for welfare in society, frustrating market entry, and with little trade-off of the monopolists undertaking additional socially-beneficial innovation. 
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Counter-and Supporting Narratives
In keeping with Commission protocol, a consultation period of two months followed the Preliminary Report, during which over 70 interested partiesincluding consumer associations, national regulators, originator companies, generic companies, insurance associations, and others -voiced their perspectives on the issues raised (see Table 1 
Preliminary Report is clearly influenced by generic claims as to the alleged potential harm that may be suffered if an interim injunction is granted, it makes nothing but passing reference to the harm that is suffered by an innovator if no injunction is granted."
At the same time as they attribute wrongdoings to players and practices elsewhere in the market, the originator companies attempt to discredit the narrative emerging from the Preliminary Report on substantial and methodological -that is, epistemological -grounds:
" • A Community patent and a unified specialised patent litigation system in Europe would reduce administrative burdens and uncertainty for companies.
• Recent initiatives of the European Patent Office (EPO) to ensure a high quality standard of patents granted and to accelerate procedures were welcomed. This included measures taken in March 2009 to limit the possibilities and time periods during which voluntary divisional patent applications could be filed (a so-called "raising the bar" exercise).
While attributing future action imperatives mainly to its own institutions, the Commission also urged member states to streamline pricing and reimbursement policies and to significantly accelerate approval procedures for generic medicines.
In many stakeholders' (especially the originators') view, the 2009 Final Report was more "balanced" than the Preliminary Report; toning down the "emotive rhetoric" (Hull 2009 ) some had perceived, and found offence at, in the Preliminary Report. For instance, the uses of the terms "defensive," "secondary,"
or "weak" patent, which in the Preliminary Report were used to highlight and deconstruct the market practices associated with these market objects, were in the Final Report aligned with the dispassionate language of European patent law, which only knows of "patents" as awarded on the basis of technical novelty rather than patient value. Unsurprisingly, the Commission's shift in tone was welcomed by EFPIA, the trade group representing large pharmaceutical companies. In a statement, the group found that its counter-narrative's objective of refocusing the discussion from potential industry wrongdoings towards streamlining the EU patent system was adequately reflected in the Final Report. EFPIA also noted that the Final Report "failed to substantiate" earlier allegations that patenting strategies of some pharma companies dampened innovation.
Narratives and performances
So through the Final Report, were narratives reconciled and the status quo ante bellum re-established? Not quite. As mentioned, we can expect an authoritative narrative to include an elaboration of some end point, be it legal or economic, to which a majority of actors can subscribe. 
Discussion
Tracing a market controversy through its public textscape, as we have done in the analysis above, gives an insight into to the role narratives play in agencing markets. While we could not access the private processes of narrative construction (cf. Abolafia 2010) beyond the public texts themselves, we have traced how the development of the Inquiry's initial, counter, and authoritative narratives shape the market's agencements. The pharmaceutical market is a prototypical "concerned" market (Geiger, Harrison, Kjellberg and Mallard 2014) , where regulatory concerns, patient interests, government costs, "big" and "small" pharma, global and local agendas coalesce and compete with patent law, scientific innovation, and drug lifecycles. Such concerned markets are shaped by a multitude of actors, voices, interests and values, and while changing their sociotechnical agencements is bound to be fraught with difficulty and challenge, they are also spaces where dissenting voices can be made audible.
As market representations that highlight temporality, market narratives are implicated in these markets' agencements and simultaneously contribute to their reordering. As claimed by Callon (2007, p. 320) , there is "nothing left outside the agencement", and a change in narrative will inevitably lead to changes elsewhere in this textual and material assemblage. In our case, the process of juxtaposing rival narratives and reaching the compromise narrative moved the European Union a step closer to bringing the Unitary Patent to reality. It also compelled that same actor to follow up on some of the potential misconducts unearthed during the Inquiry. Finally, it likely prompted the pharmaceutical industry to ensure that its future actions were consistent with how they had been narrated during the Inquiry. Representations, in our case as narratives, have agency, but as Butler (2010) claims, they act in a perlocutionary rather than illocutionary sense; that is, only if market actors buy into and invest in the "possible worlds" they emplot.
In some contrast to Beckert (2013) , whose concern lies with mental representations and collective beliefs rather than with socio-technical agencements, we contend that not every "fiction" has the potential to become performative. As we showed in our analysis, the contests around "whose narrative" would succeed were partly fought out in terms of the (material) accountability of their claims and partly in terms of how they enrolled supporting actors and their narratives. Pollock and Williams (2010) examine "successful"
promissory organizations, such as Gartner, in relation to how they mobilize promises about new technologies and how they organize the promissory space.
The narratives we traced in this paper acted in a similar manner: They emplotted (widely known) past and existing market practices by mobilizing the sector's two opposing discourses of innovation -societal welfare and innovative rents. They then emplotted changes in the market's agencements into the intertextual narrative with a fictional end point where both discourses are more or less in balance; an end point that, as a compromise narrative, is preferable to the market's status quo. Narrating market practices in this context opened up the possibility of economic reordering and market innovation.
It is a relatively small step from this analysis of the performative role of narratives to the issue of power, or "which narrative" will be invested in and where market innovation becomes a collective task, and where the question to be resolved is one of equipping market actors to shape the markets that they promote. In the context of EU biofuel sustainability schemes, Laurent (2014) suggests the term "European agencements" instead of "market agencements" to highlight how the political lies within the qualification of economic objects and spaces.
We demonstrated one case where a public inquiry "problematized" (Callon 1986 ) an existing sociotechnical agencement and opened up a forum for discussion and contestation around different ways of reordering the agencement in question. In our case, narratives and counter-narratives were fused into a carefully framed hybrid master or authoritative narrative, to which ostensibly all interested actors could subscribe. As with any attempt at framing, though, the spillovers of those alternative or suppressed narratives are still visible and lurking behind the master narrative (cf. Callon 1998; . The controversy may be closed down for now, but concerned publics remain, and their rival narratives are still circulating and enrolling others.
As devices, narratives bring their own processes, and temporality is critical. A narrative becomes a way of reconstructing the past, as through inferences of causality, and of envisaging a future end-point to a process, which is often abstract, as in the equilibrium of neoclassical economics, or the conditions that allow it to reach an end point, such as of a legal process. But these narratives inform and shape the visions and materialities of a market, and so provide a basis for sorting out current practices into helpful and unhelpful, fair and unfair. Simply put, once debated in the open, things could just not remain unchanged -after all, "discourse produces the effects that it names", albeit in a reiterative manner (Butler 1999, p. 236) . Narratives and counter-narratives are powerful devices of political and economic action because they offer a temporal shape to a market and identify, contest, and provide a critique of the uses of some practices and tools.
Conclusion
Our overarching concern in this paper lies with how markets come to be innovated, by exploring in more detail the hitherto under-researched link between market representations and market agencements. Moving from market representations to market narratives allowed us to trace how, in a market, existing practices become emplotted and related to "possible worlds" or futures that then become mobilized in socio-technical agencements. The narratives described in this study link into broad discourses around the pharmaceuticals industry, of innovation, welfare, and public good.
Fundamentally, these discourses attempt to resolve whether society is better off having producers earning monopoly profits so as to facilitate significant research and development, or whether it is preferable to subject producers to market entry and price competition. Both possibilities are beset by uncertainty:
Will the companies actually invest in novel research and development projects?
Will lower cost products produced in more competitive markets be of comparable quality to those produced presently? What else needs to be in place so as to militate against any unfavorable outcomes?
As we have shown, narratives are not self-fulfilling prophecies that in and of themselves produce realities. Rather, as with Butler (2010) , it is precisely by emplotting such uncertainties, relating them to existing and future market agencements, juxtaposing and opening them up to the possibility of misfires, that these narratives become performative. Market narratives become promissoriesbut only if and when they remain open to being wrong. We hope that our study will inspire researchers to further develop the complex relationships between agencements, expectations, futures, representations, performativity, and representations in markets that we have started to trace.
1
It was the first time that a Sector Inquiry opened with such raids, and for many commentators they represented an application that was unprecedented in its force and signalling value of the EU's antitrust regulations. To justify this approach, the FAQ Section of the DG Comp website reads: "The kind of information the Commission will be examining in this inquiry, notably concerning the use of intellectual property rights, litigation and settlement agreements covering the EU, is by its nature information that companies tend to consider highly confidential. Such information may also be easily withheld, concealed or destroyed. The Commission is keen to have immediate access to all such company information and has therefore ordered unannounced inspections." 2 A disclaimer is necessary at this point. In 'Representing Reality', Jonathan Potter (1996) points out that any attempt at analysing or deconstructing discourse within a conventional textual narrative such as a scientific text -as with the present one -is essentially a self-referential exercise. (Social) scientific texts use the same procedures as other texts when they "separate descriptions from their own interests and produce them as neutral and external; that is, to give them a quality of out-there-ness" (p. 15) are used. As a narrative in itself, the scientific text is always partial and incomplete. So too, by extension, is this article.
3
It is noteworthy that this Inquiry was from the outset couched in terms of safeguarding competition rather than public welfare, though the narratives constructed referred to both discourses.
4
The publication of this report followed a large-scale investigation by DG Comp including the analysis of more than 20,000 pages of texts obtained during the January 2008 inspections, interviews with a range of stakeholders, surveys of pharmaceutical companies and other stakeholders and requests for information.
5
One may note that the Rt. Hon. Sir Robin Jacob, Court of Appeal of England and Wales, found none of these market practices to be either remarkable or novel in his speech at the Commission Presentation of the PR.
6
It needs to be mentioned that some originator companies are also manufacturers of generic medicines and that many generic firms are large global entities, so this separation is not quite as clear-cut as made out here.
7
The Inquiry Report specifically excludes generic price competition from its purview.
8
This throws up interesting reflections on the reach and longevity of reports, as well as on the fact that the intertextuality is both synchronous and diachronous -older versions do not necessarily disappear when they are replaced with newer ones, such that the making of these texts remains visible.
9
So-called pay-for-delay transactions or those which limit market entry for generic companies and include value transfers from originator to generic company.
